Genetic Study of Families With High Frequency of Hodgkin Lymphoma

NCT02795013 | Completed

• 1 other identifier: FAMHL
• Study Type: observational
• Target: 27
• Locations: 1 country
• Sites: 1

Brief Summary

Hodgkin lymphoma (HL) is a relatively rare disorder with known familiar aggregation (i.e. HL in more than one child, or parent and child). Because affected individuals in familial HL are genetically related, the existence of such families has long been considered as evidence in support of a genetic basis of HL susceptibility. However, it is largely unknown which genetic variations are responsible for recurring HL in families. Because the effects of genetic variants are likely to be strong in familial HL, identification of such variations will potentially reveal biological pathways critical to the pathogenesis of HL. PRIMARY OBJECTIVE:

• To perform genome-wide sequencing of families with recurring Hodgkin lymphoma cases (affected as well as non-affected family members) to identify potential disease-causing germline genetic variations. SECONDARY OBJECTIVE:
• To describe demographic and clinical features of the affected families.

Conditions

Hodgkin Lymphoma

Keywords

Genetic studies; Pediatric

Outcome Measures

Primary Outcomes (1)

• Germline genetic variations

  Whole exome sequencing of affected and unaffected individuals in these families will be performed. Genetic variants potentially related to HL will be identified on the basis of its co-segregation with HL disease status (e.g., unique variants in individuals affected by HL would be considered as risk variants). Family members without HL (regardless of any other history of malignancy) will be considered as control and be compared against members with HL.

  Once, within 1 month of enrollment

Study Arms (2)

Participants with Hodgkin Lymphoma

Those with a confirmed diagnosis of Hodgkin Lymphoma (HL) and family members who consent and enroll in this study.

Family Members without Hodgkin Lymphoma

Those unaffected by HL will serve as a control group to compare with those with HL.

Eligibility Criteria

• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Patients with a confirmed diagnosis of Hodgkin Lymphoma (HL), and family members of the patient, either affected or unaffected by a malignancy.

You may qualify if:

• Patient with HL diagnosed ≤ 21 years of age with a first-degree relative also diagnosed with HL.
• Family members of the patient, either affected or unaffected by a malignancy who agree to participate in the study.
• Research participant or legal guardian, as appropriate, must provide informed consent for this protocol.

You may not qualify if:

• Inability or unwillingness of research participant or legal guardian/representative to give written informed consent.

Sponsors & Collaborators

• St. Jude Children's Research Hospital: lead
• HudsonAlpha Institute for Biotechnology: collaborator

Study Sites (1)

St. Jude Children's Research Hospital

Memphis, Tennessee, 38105, United States

Location

Related Links

• St. Jude Children's Research Hospital
• Clinical Trials Open at St. Jude

Biospecimen

Retention: SAMPLES WITH DNA

Saliva, minimal blood, or tumor will be retained for whole exome sequencing.

MeSH Terms

Conditions

Hodgkin Disease

Condition Hierarchy (Ancestors)

Lymphoma; Neoplasms by Histologic Type; Neoplasms; Lymphoproliferative Disorders; Lymphatic Diseases; Hemic and Lymphatic Diseases; Immunoproliferative Disorders; Immune System Diseases

Study Officials

• Jamie Flerlage, MD

  St. Jude Children's Research Hospital

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Observational Model: CASE CONTROL
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: June 6, 2016
• First Posted: June 9, 2016
• Study Start: August 17, 2016
• Primary Completion: February 27, 2018
• Study Completion: February 27, 2018
• Last Updated: September 13, 2018

Record last verified: 2018-09

Locations

US (1)